Kumar A, Sen A P, Saxena P R, Gulati A
Department of Pharmaceutics & Pharmacodynamics, University of Illinois at Chicago 60612, USA.
Artif Cells Blood Substit Immobil Biotechnol. 1997 Jan-Mar;25(1-2):85-94. doi: 10.3109/10731199709118900.
Diaspirin crosslinked hemoglobin (DCLHb Baxter Healthcare Corp., Round Lake, IL, USA), a hemoglobin-based blood substitute has been found to be an effective resuscitative agent following hemorrhage in animals. The present study was undertaken to determine the effect of DCLHb on microvascular perfusion in the brain and kidney following hemorrhage in anaesthetized, male Sprague Dawley rats using laser Doppler flowmetry. Hemorrhage was induced by withdrawal of arterial blood at a rate of 0.5 to 1.0 ml/min until blood pressure of 35-40 mmHg was achieved. This was maintained for up to 30 min. The arterial blood pH, pO2, pCO2 and total hemoglobin (THb) were monitored. Hemorrhage significantly decreased pH, pCO2 and THb and increased pO. Hemorrhage significantly decreased (26%) brain blood perfusion due to a decrease (17%) in the concentration of moving red blood cells (CMBC). In the kidney there was a greater decrease (65%) in blood perfusion due to a significant decrease in both CMBC (28%) and red blood cell velocity (49%). Resuscitation with vehicle (Ringer's lactate, 4 ml/kg, i.v.) did not produce any improvement in cerebral and renal blood perfusion. Resuscitation with DCLHb (400 mg/kg, i.v.) improved perfusion in the brain (112%) due to an increase in the CMBC (69%) and the velocity of red blood cells (33%). Similarly, in the kidney, DCLHb increased perfusion (178%) by increasing CMBC (55%) and red blood cell velocity (89%) of hemorrhaged rats. The increase in renal blood perfusion was more marked (p < 0.001) than the changes in cerebral blood perfusion following resuscitation with DCLHb in hemorrhaged rats. It is concluded that DCLHb can significantly increase cerebral and renal blood perfusion of hemorrhaged rats and this effect may contribute to its efficacy as a resuscitative solution.
双阿司匹林交联血红蛋白（DCLHb，美国伊利诺伊州圆湖市百特医疗保健公司生产）是一种基于血红蛋白的血液替代品，已被发现在动物出血后是一种有效的复苏剂。本研究旨在使用激光多普勒血流仪，确定DCLHb对麻醉的雄性Sprague Dawley大鼠出血后脑和肾脏微血管灌注的影响。以0.5至1.0毫升/分钟的速度抽取动脉血诱导出血，直至血压达到35 - 40毫米汞柱。维持该状态长达30分钟。监测动脉血pH值、pO2、pCO2和总血红蛋白（THb）。出血显著降低了pH值、pCO2和THb，并升高了pO。由于移动红细胞浓度（CMBC）降低17%，出血显著降低了26%的脑血流灌注。在肾脏，由于CMBC显著降低28%和红细胞速度降低49%，血流灌注下降幅度更大，达65%。用载体（乳酸林格氏液，4毫升/千克，静脉注射）复苏并未改善脑和肾脏的血流灌注。用DCLHb（400毫克/千克，静脉注射）复苏可使脑灌注改善112%，这是由于CMBC增加69%和红细胞速度增加33%。同样，在肾脏，DCLHb通过增加出血大鼠的CMBC 55%和红细胞速度89%，使灌注增加178%。出血大鼠用DCLHb复苏后，肾脏血流灌注的增加比脑血流灌注的变化更显著（p < 0.001）。结论是，DCLHb可显著增加出血大鼠的脑和肾脏血流灌注，这种作用可能有助于其作为复苏液的疗效。
